Fratagene Therapeutics. September 2019. The CureFA Foundation, Rye, NY, USA, has joined the ownership of Fratagene Therapeutics. The CureFA foundation funds scientific projects and industry partnership that leverage new technologies for the treatment and cure of Friedreich ataxia. Its assets in Fratagene will help support the first clinical trial aimed at assessing the safety and efficacy of etravirine in FA patients.
Friday, September 20, 2019
Subscribe to:
Posts (Atom)
